View Older Stories View More Recent Stories
-
Incyte (INCY) PT Raised to $62 at UBS
-
William Blair Comments on Incyte (INCY) CEO Transition
-
Citi Comments Incyte (INCY) New CEO
-
Incyte (INCY) new CEO sparks chatter
-
Incyte (INCY) CEO change timing 'feels right' - Stifel
-
Incyte (INCY) Appoints Bill Meury as Next CEO
-
Incyte (INCY) announces that FDA extends review for Ruxolitinib cream
-
Incyte (INCY) Announces FDA Approval of Monjuvi in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
-
FDA approves Incyte's tafasitamab-cxix for relapsed or refractory follicular lymphoma
-
Incyte (INCY): Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
-
Oppenheimer Reiterates Outperform Rating on Incyte (INCY)
-
Incyte (INCY) PT Raised to $82 at Jefferies
-
Stifel Upgrades Incyte (INCY) to Buy
-
Incyte (INCY) and Specialised Therapeutics expand partnership, add to oncology portfolio
-
UBS Reiterates Neutral Rating on Incyte (INCY)
-
Stifel Reiterates Hold Rating on Incyte (INCY)
-
TD Cowen Reiterates Buy Rating on Incyte (INCY)
-
JPMorgan Reiterates Neutral Rating on Incyte (INCY)
-
Citi Reiterates Buy Rating on Incyte (INCY)
-
BMO Capital weighs in on Incyte (INCY) following mCALR antibody data
-
Incyte (INCY) Announces Multiple Presentations
-
UBS Reiterates Neutral Rating on Incyte (INCY)
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Incyte (INCY) Announces FDA Approval of Zynyz Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
-
Incyte (INCY) and Novartis (NVS) entered into settlement agreement
-
Incyte (incy) PT Raised to $89 at BofA Securities
-
Incyte (INCY) Tops Q1 EPS by 12c
-
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
-
Incyte (INCY) PT Lowered to $72 at Truist Following Povo Data
-
William Blair Downgrades Incyte (INCY) to Market Perform
-
Citi on Incyte (INCY): 'We are buyers on weakness'
-
Incyte (INCY) PT Lowered to $75 at Jefferies
-
Incyte (INCY) call put ratio 2 calls to 1 put as share price down 7.6%
-
Mizuho Reiterates Neutral Rating on Incyte (INCY)
-
RBC Capital on Incyte (INCY): 'Povo Looks Mostly as We Expected', 'We expect modest weakness today'
-
Incyte (INCY) Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
-
Citizens JMP Reiterates Market Perform Rating on Incyte (INCY)
-
TD Cowen Reiterates Buy Rating on Incyte (INCY) Post Mixed Trial Data
-
Incyte (INCY) and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
-
Incyte (INCY) PT Raised to $88 at TD Cowen Following a 'Strong' Q4
-
Incyte (INCY) PT Lowered to $68 at RBC Capital
-
Incyte (INCY) PT Lowered to $88 at Citi
-
Incyte (INCY) PT Raised to $77 at Stifel
-
Incyte (INCY) Misses Q4 EPS by 8c
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
Oppenheimer Reiterates Outperform Rating on Incyte (INCY)
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Incyte (INCY) Late-Breaking Tafasitamab Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
-
Incyte (INCY) PT Raised to $86 at TD Cowen
-
Incyte (INCY) call put ratio 2.1 calls to 1 put amid wide price movement
